Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q96RY7
UPID:
IF140_HUMAN
Alternative names:
WD and tetratricopeptide repeats protein 2
Alternative UPACC:
Q96RY7; A2A2A8; D3DU75; O60332; Q9UG52
Background:
Intraflagellar transport protein 140 homolog (IFT140) is a crucial component of the IFT complex A, essential for retrograde ciliary transport and GPCR entry into cilia. It plays a pivotal role in ciliogenesis and cilium maintenance, impacting the development and function of ciliated cells. IFT140 is vital for the development and maintenance of photoreceptor cells' outer segments, facilitating opsin delivery.
Therapeutic significance:
IFT140's involvement in short-rib thoracic dysplasia 9 and retinitis pigmentosa 80 highlights its therapeutic potential. Understanding IFT140's role could open doors to novel therapeutic strategies for these ciliopathies, offering hope for patients suffering from these genetic disorders.